SEARCH

SEARCH BY CITATION

References

  • 1
    Reed KE, Rice CM. Overview of hepatitis C virus genome structure, polyprotein processing, and protein properties. Curr Top Microbiol Immunol 2000; 242:5584.MEDLINE
  • 2
    Nelson DR, Marousis CG, Davis GL, Rice CM, Wong J, Houghton M, Lau JY. The role of hepatitis C virus-specific cytotoxic T lymphocytes in chronic hepatitis C. J Immunol 1997; 158:14731481.MEDLINE
  • 3
    Satoi J, Murata K, Lechmann M, Manickan E, Zhang Z, Wedemeyer H, et al. Genetic immunization of wild-type and hepatitis C virus transgenic mice reveals a hierarchy of cellular immune response and tolerance induction against hepatitis C virus structural proteins. J Virol 2001; 75:1212112127.MEDLINE
  • 4
    Lai MMC, Ware CF. Hepatitis C Virus Core Protein: Possible Roles in Viral Pathogenesis. In: HagedornCH, RiceCM, eds. The hepatitis C viruses. Berlin: Springer-Verlag; 2000; 117134.
  • 5
    Pawlotsky JM. Diagnostic tests for hepatitis C. J Hepatol 1999; 31(Suppl 1):7179.MEDLINE
  • 6
    Pawlotsky JM. Molecular diagnosis of viral hepatitis. Gastroenterology 2002 (in press).
  • 7
    Orito E, Mizokami M, Tanaka T, Lau JY, Suzuki K, Yamauchi M, et al. Quantification of serum hepatitis C virus core protein level in patients chronically infected with different hepatitis C virus genotypes. Gut 1996; 39:876880.MEDLINE
  • 8
    Aoyagi K, Ohue C, Iida K, Kimura T, Tanaka E, Kiyosawa K, Yagi S. Development of a simple and highly sensitive enzyme immunoassay for hepatitis C virus core antigen. J Clin Microbiol 1999; 37:18021808.MEDLINE
  • 9
    Tanaka E, Ohue C, Aoyagi K, Yamaguchi K, Yagi S, Kiyosawa K, Alter HJ. Evaluation of a new enzyme immunoassay for hepatitis C virus (HCV) core antigen with clinical sensitivity approximating that of genomic amplification of HCV RNA. Hepatology 2000; 32:388393.MEDLINE
  • 10
    Courouce AM, Le Marrec N, Bouchardeau F, Razer A, Maniez M, Laperche S, Simon N. Efficacy of HCV core antigen detection during the preseroconversion period. Transfusion 2000; 40:11981202.MEDLINE
  • 11
    Peterson J, Green G, Iida K, Caldwell B, Kerrison P, Bernich S, et al. Detection of hepatitis C core antigen in the antibody negative “window” phase of hepatitis C infection. Vox Sang 2000; 78:8085.MEDLINE
  • 12
    Icardi G, Ansaldi F, Bruzzone BM, Durando P, Lee S, de Luigi C, Crovari P. Novel approach to reduce the hepatitis C virus (HCV) window period: clinical evaluation of a new enzyme-linked immunosorbent assay for HCV core antigen. J Clin Microbiol 2001; 39:31103114.MEDLINE
  • 13
    Lee SR, Peterson J, Niven P, Bahl C, Page E, DeLeys R, et al. Efficacy of a hepatitis C virus core antigen enzyme-linked immunosorbent assay for the identification of “window-phase” blood donations. Vox Sang 2001; 80:1923.MEDLINE
  • 14
    Saldanha J, Lelie N, Heath A. Establishment of the first international standard for nucleic acid amplification technology (NAT) assays for HCV RNA. Vox Sang 1999; 76:149158.MEDLINE
  • 15
    Jorgensen PA, Neuwald PD. Standardized hepatitis C virus RNA panels for nucleic acid testing assays. J Clin Virol 2001; 20:3540.MEDLINE
  • 16
    Bouvier-Alias M, Remire J, Darthuy F, Dhumeaux D, Pawlotsky JM. Standardized quantification of hepatitis C virus RNA with third-generation “branched DNA” (bDNA) signal amplification assay. Hepatology 2001; 34(Part 2):56A.
  • 17
    Lam NP, Neumann AU, Gretch DR, Wiley TE, Perelson AS, Layden TJ. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology 1997; 26:226231.MEDLINE
  • 18
    Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, Perelson AS. Hepatitis C viral kinetics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998; 282:103107.MEDLINE
  • 19
    Maillard P, Krawczynski K, Nitkiewicz J, Bronnert C, Sidorkiewicz M, Gounon P, et al. Nonenveloped nucleocapsids of hepatitis C virus in the serum of infected patients. J Virol 2001; 75:82408250.MEDLINE
  • 20
    Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958965.MEDLINE
  • 21
    Zeuzem S, Herrmann E, Lee JH, Fricke J, Neumann AU, Modi M, et al. Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a. Gastroenterology 2001; 120:14381447.MEDLINE
  • 22
    Neumann AU, Zeuzem S, Brunda MJ, Hoffman JH. Rapid viral response to treatment with pegylated (40 kd) interferon alfa-2a (Pegasys) is strongly predictive of a sustained virologic response in patients with chronic hepatitis C (CHC). Hepatology 2000; 32(Part 2):318A.
  • 23
    Poynard T, McHutchison J, Goodman Z, Ling MH, Albrecht J. Is an “a la carte” combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C ? Hepatology 2000; 31:211218.MEDLINE
  • 24
    Marcellin P, Boyer N, Gervais A, Martinot M, Pouteau M, Castelnau C, et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med 1997; 127:875881.MEDLINE
  • 25
    McHutchison JG, Davis GL, Esteban-Mur R, Poynard T, Ling MH, Garaud JJ, Albrecht J. Durability of sustained virologic response in patients with chronic hepatitis C after treatment with interferon alpha-2b alone or in combination with ribavirin. Hepatology 2001; 34(Part 2):244A.